LABORATORIO REIG J.EO 05
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmacy, food, and animal food. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables … Read more
LABORATORIO REIG J.EO 05 (FEQ1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LABORATORIO REIG J.EO 05 (FEQ1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LABORATORIO REIG J.EO 05 - Net Assets Trend (None–None)
This chart illustrates how LABORATORIO REIG J.EO 05's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LABORATORIO REIG J.EO 05 (None–None)
The table below shows the annual net assets of LABORATORIO REIG J.EO 05 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LABORATORIO REIG J.EO 05's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LABORATORIO REIG J.EO 05 Competitors by Market Cap
The table below lists competitors of LABORATORIO REIG J.EO 05 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shape Australia Corporation Ltd
AU:SHA
|
$53.29 Million |
|
Tarkim Bitki Koruma Sanayi ve Ticaret A.S.
IS:TARKM
|
$53.30 Million |
|
Subex Limited
NSE:SUBEXLTD
|
$53.30 Million |
|
Zona Franca de Iquique S.A
SN:ZOFRI
|
$53.32 Million |
|
Panoro Minerals Ltd
OTCQB:POROF
|
$53.25 Million |
|
DR.Wu Skincare Co Ltd
TWO:6523
|
$53.23 Million |
|
TDC SOFT Inc
MU:TD4
|
$53.22 Million |
|
Grande Royal Orchid Hospitality Real Estate Investment Trust with Buy-Back Condition
BK:GROREIT
|
$53.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LABORATORIO REIG J.EO 05's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LABORATORIO REIG J.EO 05's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LABORATORIO REIG J.EO 05 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LABORATORIO REIG J.EO 05's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LABORATORIO REIG J.EO 05 (FEQ1) | €- | N/A | N/A | $53.25 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |